(Q38084168)

28 August 2017

A review on cholinesterase inhibitors for Alzheimer's disease (English)

1 reference

28 August 2017

0 references

Preet Anand

1

1 reference

PubMed ID

23435942

28 August 2017

Baldev Singh

series ordinal

2

1 reference

28 August 2017

24 February 2013

1 reference

Archives of Pharmacal Research

28 August 2017

1 reference

28 August 2017

36

1 reference

28 August 2017

4

1 reference

28 August 2017

375-399

1 reference

https://scigraph.springernature.com/pub.10.1007/s12272-013-0036-3

28 August 2017

0 references

cites work

Melatonin role in the mitochondrial function.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2-phenyldihydro-2H-pyrrolo[3,4-d]isoxazol-5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8]naphthyridine isosteres: a new class of potent and selective acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Aminopyridazines as acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

p-Aminobenzoic acid derivatives as acetylcholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Inhibition of acetylcholinesterase by coumarins: the case of coumarin 106.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

The pharmacology of galanthamine and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis and structure-activity relationships of open D-Ring galanthamine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis of new indole derivatives structurally related to donepezil and their biological evaluation as acetylcholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Acetylcholinesterase inhibition by flavonoids from Agrimonia pilosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

The nitric oxide donor, O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO), protects against cadmium-induced hepatotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

O-Hydroxyl- or o-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-β aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

The neuroprotective role of melatonin against amyloid beta peptide injected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and biological evaluation of coumarin derivatives tethered to an edrophonium-like fragment as highly potent and selective dual binding site acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Rational approach to discover multipotent anti-Alzheimer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Reversible and irreversible inhibitory activity of succinic and maleic acid derivatives on acetylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Tacrine for Alzheimer's disease. Which patient, what dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Oxidative stress in Alzheimer patients in different stages of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0036-3

10.1007/S12272-013-0036-3

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

23435942

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23435942